Chonluten is a trade designation covering the tripeptide Glu-Asp-Gly. This article sets out the sequence, the mass a buyer should expect to see confirmed, how the compound behaves analytically, and what a supplier ought to publish about it. It makes no claim about what the compound does and contains no preparation, handling or dosing guidance.
The sequence behind the name
Chonluten is Glu-Asp-Gly, abbreviated EDG: three standard L-amino acids, no modifications, average free-acid mass of approximately 319 g/mol.
Note how close that is to Cartalax at 333. A 14 Da difference between two compounds sold under different names in the same catalogue category is a small margin, and it is one reason mass confirmation on this class of compound has to be read carefully rather than glanced at.
Names that are not chemical identifiers
Like Cartalax and Epithalon, Chonluten is a coined designation rather than a systematic name, so it carries no structural information on its own. Anything you want to know about what is in the vial has to come from a published sequence and a published analysis, not from the label.
It is also spelled inconsistently across vendors — chonluten, khonluten, T-34 in some older material — which makes cross-referencing by name unreliable. Cross-reference by sequence instead.
Analytical behaviour
EDG is the most polar of the common short bioregulator sequences: two acidic residues and a glycine, no hydrophobic side chain anywhere. On a C18 column it retains very weakly and elutes early, in the region where salts and polar synthesis residues also appear.
There is no aromatic residue in the sequence, so ultraviolet detection at 280 nm sees nothing. Detection has to be at the peptide bond, around 214 nm, where the mobile phase itself absorbs more and a well-chosen gradient matters more. A supplier reporting a purity figure for Chonluten without naming the wavelength and gradient has not given you enough to evaluate the number.
What an analysis should show
Column chemistry and dimensions, mobile phase and gradient, detection wavelength, retention time, integrated peak area, and a mass confirmation consistent with a 319 g/mol free acid. Separately: net peptide content and the counter-ion form. On a peptide this small the counter-ion is a large fraction of the vial mass, so the difference between chromatographic purity and net peptide content is substantial and both numbers are needed.
Confirming identity independently
Query public chemical databases on the sequence rather than the trade name. Our product pages carry identity links that run those queries directly, which is the appropriate way to resolve a designation that exists mainly as a commercial label.
How Chonluten is supplied here
Chonluten 20mg ships as a lyophilised powder in a sealed vial with an independent reverse-phase HPLC analysis published on the product page, alongside net peptide content, counter-ion form and vial size. Vials carry no batch or lot numbers and are matched to their published test by crimp and cap colour.
Frequently asked questions
What is the sequence of Chonluten?
Glu-Asp-Gly (EDG).
What is the molecular weight of Chonluten?
Approximately 319 g/mol as the free acid; higher as a salt, which is why the counter-ion must be stated.
Is Chonluten the same as Bronchogen?
No. Bronchogen is reported as Ala-Glu-Asp-Leu, a tetrapeptide with a hydrophobic C-terminal residue. Chonluten is a three-residue sequence with no hydrophobic side chain at all. They are different compounds and behave differently on a column.
Why can I not compare purity figures between two Chonluten suppliers?
Because for a compound this polar the purity figure is heavily method-dependent. Two vendors running different gradients on different columns at different wavelengths will produce different numbers from the same material. Compare methods first, then numbers.
Research use only. All products supplied by Battle Born Peptides are laboratory reference materials for in-vitro research and analytical use by qualified professionals. They are not drugs, foods, dietary supplements, cosmetics or medical devices; they are not approved by the FDA or any other regulator for use in humans or animals; and they are not intended to diagnose, treat, cure, mitigate or prevent any disease, or to affect the structure or any function of the body of humans or animals. Nothing in this article is preparation, handling or dosing guidance. See our full research-use terms.